Human sphingosine lyase polypeptides

Details Human sphingosine lyase polypeptides Human sphingosine lyase polypeptides

2000-12-19

2003-02-18

Kunz, Gary (Department: 1647)

Chemistry: molecular biology and microbiology

Enzyme , proenzyme; compositions thereof; process for...

Lyase

C530S350000, C435S183000

Reexamination Certificate

active

06521437

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides, to their use in therapy and in identifying compounds which may be agonists, antagonists and/or inhibitors which are potentially useful in therapy, and to production of such polypeptides and polynucleotides.
BACKGROUND OF THE INVENTION
The drug discovery process is currently undergoing a fundamental revolution as it embraces ‘functional genomics’, that is, high throughput genome- or gene-based biology. This approach as a means to identify genes and gene products as therapeutic targets is rapidly superseding earlier approaches based on ‘positional cloning’. A phenotype, that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.
Functional genomics relies heavily on high-throughput DNA sequencing technologies and the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available. There is a continuing need to identify and characterise further genes and their related polypeptides/proteins, as targets for drug discovery.
SUMMARY OF THE INVENTION
The present invention relates to SPHINGLY, in particular SPHINGLY polypeptides and SPHINGLY polynucleotides, recombinant materials and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including the treatment of cancers, cardiovascular disorders, thrombosis, atherosclerosis, wound healing, stroke, CNS disorders, neuronal disorders and apoptosis, hereinafter referred to as “the Diseases”, amongst others. In a further aspect, the invention relates to methods for identifying agonists and antagonists/inhibitors using the materials provided by the invention, and treating conditions associated with SPHINGLY imbalance with the identified compounds In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate SPHINGLY activity or levels.


REFERENCES:
patent: 6187562 (2001-02-01), Duckworth et al.
Zhou et al. “Identification of the First Mammalian Sphingosine Phosphate Lyase Gene and Its Functional Expression in Yeast”, Biochem. Res. Comm., vol. 242, pp. 502-507 (1998).
Saba et al. “The BSTI Gene ofSaccharomyces cerevisiaeIs the Sphingosine-1-phosphate Lyase”, J. Biol. Chem., vol. 272, pp. 26807-26090 (1997).
GenBank Accession #AF036894, Marra, et al., Feb. 24, 1998 (Rel. 54, Last updated, Version 1).
GenBank Accession #U51031, Johnston, et al., Aug. 12, 1997 (Rel. 52, Last updated, Version 4).
Boehringer Mannheim Biochemicals, 1991 Catalog, p. 557.
Smith, Elem. Mol. Neurobio, 2nded. p. 74-82 (1996).
Lazar, et al., Mol. Cell Bio., 8:1247-1252 (1988).
Burgess, et al., J. Cell Bio., 111:2129-2138 (1990).
Jenkins, et al., PCR Methods and Applications, S77-81 (1994).

Affiliated with

Also associated with

Rating

Human sphingosine lyase polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human sphingosine lyase polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human sphingosine lyase polypeptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3138969